Selective and Improved Photoannealing of Microporous Annealed Particle (MAP) Scaffolds

Pfaff, Blaise N.; Pruett, Lauren; Cornell, Nicholas J.; Rutte, Joseph de; Carlo, Dino Di; Highley, Christopher B.; Griffin, Donald R.

doi:10.1021/acsbiomaterials.0c01580

Cited by 22 publications

(30 citation statements)

References 19 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[261][262][263][264][265][266][267][268][269] Microgel-based MAP scaffolds can have different interstitial pore sizes by changing the microgel diameter. [270,271] These micronscale interstitial pores facilitate cell infiltration, as the cells do not need to degrade the material to create an open path. The internal network structure of the microgel building blocks mediates softness and can present biomolecular cues, such as growth factors.…”

Section: Microgels As Scaffolds For Tissue Regenerationmentioning

confidence: 99%

Translating Therapeutic Microgels into Clinical Applications

Kittel

Kuehne

Laporte

2021

Adv Healthcare Materials

View full text Add to dashboard Cite

Microgels are crosslinked, water‐swollen networks with a 10 nm to 100 µm diameter and can be modified chemically or biologically to render them biocompatible for advanced clinical applications. Depending on their intended use, microgels require different mechanical and structural properties, which can be engineered on demand by altering the biochemical composition, crosslink density of the polymer network, and the fabrication method. Here, the fundamental aspects of microgel research and development, as well as their specific applications for theranostics and therapy in the clinic, are discussed. A detailed overview of microgel fabrication techniques with regards to their intended clinical application is presented, while focusing on how microgels can be employed as local drug delivery materials, scavengers, and contrast agents. Moreover, microgels can act as scaffolds for tissue engineering and regeneration application. Finally, an overview of microgels is given, which already made it into pre‐clinical and clinical trials, while future challenges and chances are discussed. This review presents an instructive guideline for chemists, material scientists, and researchers in the biomedical field to introduce them to the fundamental physicochemical properties of microgels and guide them from fabrication methods via characterization techniques and functionalization of microgels toward specific applications in the clinic.

show abstract

Section: Microgels As Scaffolds For Tissue Regenerationmentioning

confidence: 99%

Translating Therapeutic Microgels into Clinical Applications

Kittel

Kuehne

Laporte

2021

Adv Healthcare Materials

View full text Add to dashboard Cite

show abstract

“…Our investigation focused on a MAP microgel formulation that consisted of a 4‐arm polyethylene glycol (PEG)‐maleimide backbone, an enzymatically degradable peptide crosslinker, a cell adhesive peptide pendant group, and a custom MethMal annealing macromer (previously described for accelerated MAP assembly in situ [ 30 ] ). For animal studies, a minority of microgels containing immobilized thiolated heparin were included heterogeneously throughout the MAP scaffold to promote accelerated vascularization.…”

Section: Resultsmentioning

confidence: 99%

“…Microgel Production and Purification: The no-heparin 3.2 wt% (w/v) microgel precursor solution consisted of PEG-Maleimide (10 kDa, Nippon Oil Foundry, Japan), MMP-2 degradable crosslinker (Ac-GCGPQGIAGQDGCG-NH2, Watson Bio), RGD (Ac-RGDSPGGC-NH2, Watson Bio), and MethMal [30] annealing macromer. The 2.2 wt% 6 mg mL −1 heparin microgel precursor solution contained thiolated heparin which was prepared as previously described.…”

Section: Methodsmentioning

confidence: 99%

Delivery of Dissociated Islets Cells within Microporous Annealed Particle Scaffold to Treat Type 1 Diabetes

Roosa

Chhabra

et al. 2022

Advanced Therapeutics

Self Cite

View full text Add to dashboard Cite

Type 1 diabetes (T1D) is caused by the autoimmune loss of insulin‐producing beta cells in the pancreas. The only clinical approach to patient management of blood glucose that doesn't require exogenous insulin is pancreas or islet transplantation. Unfortunately, donor islets are scarce and there is substantial islet loss immediately after transplantation due, in part, to the local inflammatory response. The delivery of stem cell‐derived beta cells (e.g., from induced pluripotent stem cells) and dissociated islet cells hold promise as a treatment for T1D; however, these cells typically require re‐aggregation in vitro prior to implantation. Microporous scaffolds have shown high potential to serve as a vehicle for organization, survival, and function of insulin‐producing cells. In this study, the use of microporous annealed particle (MAP) scaffold for delivery of enzymatically dissociated islet cells, a model beta cell source, within the scaffold's interconnected pores is investigated. It is found that MAP‐based cell delivery enables survival and function of dissociated islets cells both in vitro and in an in vivo mouse model of T1D.

show abstract

“…MethMal annealing macromer was synthesized as previously described. 15 Heparin (15 000 Da, Millipore Sigma) was thiolated with PDPH (3-(2-pyridyldithio)propionyl hydrazide) as previously described. 2 Human EGF protein and ELISA kits were purchased from R&D Biosystems.…”

Section: Methodsmentioning

confidence: 99%